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Background: Endoscopic biliary stenting (EBS) is one of the most important palliative treatments for biliary tract
cancer. However, reflux cholangitis arising from bacterial adherence to the inner wall of the stent must be avoided.
We evaluated the use of EBS above the sphincter of Oddi to determine whether reflux cholangitis could be
prevented in preoperative cases.
Methods: Fifty-seven patients with primary biliary tract cancer were retrospectively recruited for the evaluation of
stent placement either above (n = 25; inside stent group) or across (n = 32; conventional stent group) the sphincter
of Oddi. We compared the stent patency periods prior to the time of surgical resection.
Results: The preoperative periods were 96.3 days in the conventional stent group and 96.8 days in the inside stent
group (P = 0.979). Obstructive jaundice and/or acute cholangitis occurred in 7 patients (28.0%) in the inside stent
group and in 15 patients (46.9%) in the conventional stent group during the preoperative period (P = 0.150). The
average patency periods of the stents were 85.2 days (range, 13–387 days) for the inside stent group and 49.1 days
(range, 9–136 days) for the conventional stent group (log-rank test: P = 0.009). The mean numbers of re-interventions
because of stent occlusion were 0.32 for the inside stent group and 1.03 for the conventional stent group (P = 0.026).
Post-endoscopic retrograde cholangiopancreatography complications occurred in 2 patients in the inside stent group
and 4 patients in the conventional stent group (P = 0.516). Postoperative liver abscess occurred in 1 patient in the
inside stent group and 5 patients in the conventional stent group (P = 0.968). Inside stent placement was the only
significant preventative factor associated with stent obstruction based on univariate (hazard ratio [HR], 0.286; 95%
confidence interval [CI], 0.114-0.719; P = 0.008) and multivariate (HR, 0.292; 95% CI, 0.114-0.750; P = 0.011) analyses.
Conclusion: Temporary plastic stent placement above the sphincter of Oddi is a better bridging treatment than
conventional stent placement in preoperative primary biliary tract cancer.Background
Endoscopic biliary stenting (EBS) is a well-established pal-
liative treatment that can be used to relive symptoms and
improve quality of life of patients with biliary tract cancer
[1,2]. EBS is also one of the most useful drainage methods
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unless otherwise stated.obstructive jaundice and/or cholangitis during the pre-
operative period [3]. However, the long-term placement of
plastic biliary stents can itself become a cause of ob-
structive jaundice and/or reflux cholangitis. In addition,
preoperative biliary drainage may be associated with an
increased incidence of postoperative morbidity and
lengthened hospital stays [4]. On the other hand, liver
resection in jaundiced patients is associated with high
morbidity and mortality rates [5]. There is still contro-
versy regarding whether preoperative biliary drainage is
essential for jaundiced patients with biliary tract cancer.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Photograph of the Amsterdam type inside stent. A
2–0 nylon thread is attached to the distal side hole to aid removal
of the inside stent, when necessary.
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ity rates following major liver resection performed for
hilar bile duct cancer are low, a finding that leads many
to believe that preoperative biliary drainage an essential
element in preoperative treatment [6,7]. Safe surgical
resections cannot be performed in patients with reflux
cholangitis, which is a life-threatening complication.
Thus, preventing reflux cholangitis by performing endo-
scopic treatment is a challenge for the preoperative
management of patients with biliary tract cancer. Recently,
some reports have stated that an inside stent is very useful
for preventing reflux cholangitis following liver transplant-
ation [8,9]. Amsterdam-type or Tannenbaum-type fluori-
nated ethylene propylene endoprostheses occupying the
entire bile duct can be used to prevent the reflux of intes-
tinal contents into the biliary tree. To allow easy removal
of the stent from the bile duct, a nylon thread is tied to
the stent via a distal hole. Inside stents are known to be
beneficial in patients with benign bile duct strictures, but
only a small amount of evidence is available for cases of
strictures associated with malignancies. According to a
previous report, no significant difference in overall stent
performance was observed between inside stents and con-
ventional stents [10]. However, that previous study evalu-
ated long patency periods of plastic stent placement
lasting until the patient’s death and also excluded cases of
malignant hilar biliary strictures. Recently, the administra-
tion of systemic chemotherapy and/or radiotherapy to pa-
tients with biliary tract cancer has been found to prolong
both progression-free survival and overall survival [11].
Chemotherapy and/or radiotherapy are essential in pa-
tients with initially unresectable biliary tract cancer. How-
ever biliary tract infection is the most severe adverse event
experienced by patients undergoing systemic chemother-
apy for biliary tract cancer. This risk must be prevented to
allow the safe continuation of systemic chemotherapy
and/or radiotherapy. Some previous reports have found
the patency period for plastic stents to be only a few
months. If an inside stent could be used to prolong the
patency period, chemotherapy and/or radiotherapy could
be safely performed prior to surgical resection. In the
present report, we retrospectively compared the use of
conventional plastic stents and inside stents in patients
with primary biliary tract cancer.
Methods
Patients
Eighty-two patients with malignant biliary strictures
underwent surgical resected at Yokohama City University
between 2006 and 2011. All patients had undergone com-
puted tomography examinations, and they had been diag-
nosed with primary biliary tract cancer by an expert
radiologist. We excluded 25 patients who had undergone
percutaneous transhepatic biliary drainage (PTBD) as theinitial treatment, and PTBD was performed following
endoscopic treatment in this study. Fifty-seven patients
were retrospectively enrolled in the present study. After
evaluating the state of the patients (based on the presence
of obstructive jaundice and/or acute cholangitis), endo-
scopic retrograde cholangiopancreatography (ERCP) was
performed. All patients underwent performed surgical
resection, and they were pathologically diagnosed with
primary biliary tract cancer. We excluded cases of pancre-
atic cancer, ampullary cancer, and intra hepatic cancer
(ICC). Most cases of pancreatic and ampullary cancer, are
not indications for inside stent placement (the distance
from the stricture to the papilla is less than 2 cm in most
cases), and ICC is a separate entity from bile duct cancer
according to surgical and pathological diagnosis, particu-
larly in Japanese guidelines. In addition, many ICCs are
characterized by expansive growth in the liver paren-
chyma, and there have been few cases of surgical resection
following preoperative biliary drainage in our institution.
According to resectability, we added preoperative che-
motherapy or chemo-radiotherapy for the treatment of
the patients with bile duct cancer. Twenty-seven patients
(47.4%) underwent preoperative chemotherapy or chemo-
radiotherapy. Patients received gemicitabine plus S-1
(gemcitabine 1,000 mg/m2 on days 1 and 8 plus S-1 60,
80, or 100 mg/d according to body surface area on days 1
through 14 of a 21-day cycle). When administered as
neoadjuvant treatment, patients normally undergo at
least three courses of this combination therapy. We re-
evaluated resectability after three courses of chemother-
apy, and if adverse events and disease progression were
not observed, down- stage chemotherapy was continued
until patients had received 12 courses. This study was
performed retrospectively and was approved by our
institution’s ethics committee (Yokohama City University
Figure 2 Endoscopic cholangiography for a case of a Bismuth type I stricture. An 8.5-Fr inside stent was placed above the sphincter of Oddi.
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was conducted in accordance with the principles of the
Declaration of Helsinki.
Preoperative endoscopic treatment
We evaluated the state of the patients and performed
ERCP using a videoduodenoscope (JF260V or TJF260V;
Olympus Medical Systems, Tokyo, Japan). The site and
type of biliary strictures were confirmed by using chol-
angiography. The strictures were first negotiated with a
0.035- or 0.025-inch-diameter Jagwire (Microvasive En-
doscopy; Boston Scientific Corp., Natick, MA, USA). If
we had difficulties inserting the guide-wire through the
stricture, we modified the placement technique by using
a more hydrophilic guide-wire (Radifocus guide-wire;
Terumo Co., Ltd., Tokyo, Japan). We inserted stents along
the guide-wire through an endoscope. If the distance from
the stricture to the sphincter of Oddi was at least 2 cm,
we used a “conventional stent” (across the sphincter of
Oddi) or an “inside stent” (above the sphincter of Oddi),Figure 3 Endoscopic cholangiography for a case of a Bismuth type IIIa stand if the distance from the stricture to the sphincter of
Oddi was less than 2 cm, we selected a conventional stent.
The conventional stents used were 7-Fr Amsterdam-type
polyethylene stents or 8.5-Fr or 10-Fr Tannenbaum-type
Teflon stents (Cook Medical Inc., Bloomington, MN,
USA), and the stent selection was at the discretion of each
endoscopist. The inside stent were Amsterdam-type or
Tannenbaum type fluorinated ethylene propylene endo-
prostheses (Cook Medical Inc.,) with a nylon thread tied
to the stent via a distal hole (Figure 1) [9]. We also classi-
fied the biliary stricture site according to the Bismuth clas-
sification [12]. We used a single stent in the majority of
cases, but 2 or 3 of the same type of stent (inside or con-
ventional) were used in some cases with Bismuth type II
or III strictures (Figures 2 and 3). An endoscopic nasobili-
ary drainage tube (ENBD tube) was used for the effective
treatment of cholangitis and/or cytological or radiological
analysis at the time of the initial endoscopic treatment in
some cases. The stents were placed during the next ses-
sion in these cases. An endoscopic sphinctectomy (EST)ricture. Two 7.0-Fr inside stents were placed above the sphincter of Oddi.
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stents. EST is a risk factor for reflux cholangitis, but we
have experienced cases of severe acute pancreatitis follow-
ing the placement of large caliber stents without EST. This
procedure was not used for the placement of small caliber
stents (7-Fr or 8.5-Fr). Following stent placement, many
patients underwent preoperative chemotherapy and/or ra-
diotherapy. If acute cholangitis and/or obstructive jaun-
dice occurred during the preoperative period, emergency
endoscopic treatment was immediately performed. We
usually removed the stent and inserted an ENBD tube
during emergency treatments. After a few days, a second
stent of the same type was once again placed using the
same technique as in the initial placement. If theseTable 1 Clinicopathological characters of the patients with co




1 BD ca (Bim) I 26
2 BD ca (Bm) I 58
3 BD ca (Bim) I 54
4 BD ca (Bmi) I 146
5 BD ca (Bim) I 49
6 BD ca (Bi) I 448
7 BD ca (Bcls) II DSC + RT 105
8 BD ca (Bi) I 40
9 BD ca (Bim) I 40
10 BD ca (Bmi) I 10
11 BD ca (Bim) I 77
12 BD ca (Bsm) I 40
13 BD ca (Bim) I 28
14 BD ca (Bim) I RT 28
15 BD ca (Bim) II 90
16 BD ca (Bmsc) II DSC 126
17 BD ca (Bcrls) I DSC + RT 217
18 BD ca (Bim) I 43
19 BD ca (Bim) I 45
20 BD ca (Bmi) I 37
21 GB ca (C) II DSC 200
22 BD ca (Bi) I 22
23 BD ca (BmC) I 45
24 BD ca (Bmi) I 20
25 BD ca (Bs) II DSC 116
26 BD ca (BmspC) II DSC 128
27 BD ca (BpcsmiJ) IV DSC 143
28 BD ca (Brplcsm) III DSC 135
29 BD ca (Brcs) III DSC 105
30 BD ca (Bcsrl) III DSC 114
31 BD ca (Bpcrls) III DSC 94
32 GB ca (GfbnC) III DSC 151
Abbreviations: JSBS: Japanese Society of Biliary Surgery, UICC: Union for International Cendoscopic treatments were not successful, or jaundice/
cholangitis did not improve even after endoscopic treat-
ments, percutaneous transhepatic biliary drainage was
performed as an additional treatment. We excluded these
percutaneous treatment cases from our analysis, because
this study evaluated the risk of cholangitis after preope-
rative endoscopic treatment. These treatments were re-
peated until the time of surgical resection.
Evaluation
We evaluated the preoperative state of patients with or
without cholangitis, and as well as the laboratory data at
the time of the pre-endoscopic treatment. We defined







Stage JBC Stage UICC
28 moderate Stage IVa Stage IIIa
12 well Stage III Stage IIIb
43 moderate Stage III Stage IIIb
70 moderate Stage III Stage IIIb
60 well Stage III Stage IIIa
10 well Stage III Stage IIIb
25 well Stage II Stage II
17 well Stage I Stage I
22 moderate Stage I Stage I
30 poor Stage III Stage I
46 well Stage II Stage I
35 poor Stage III Stage IIIb
38 well Stage III Stage IIIa
18 adenosquamous Stage II Stage II
30 moderate Stage II Stage IIIb
42 well Stage II Stage II
55 moderate Stage II Stage II
90 poor Stage III Stage IIIb
28 well Stage III Stage IIIb
55 well Stage III Stage IIIb
30 moderate Stage III Stage IIIa
28 moderate Stage III Stage IIIa
25 well Stage II Stage II
68 well Stage III Stage IIIa
59 well Stage IVb Stage IIIa
45 well Stage I Stage I
46 well Stage III Stage IIIb
40 well Stage IVa Stage IVa
30 well Stage III Stage IIIb
50 moderate Stage IVb Stage IVa
76 moderate Stage IVa Stage IVa
50 well Stage III Stage IIIa
ancer Control, BD: bile duct, DSC: Down Stage Chemotherapy. RT: radiotherapy.
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level.
Stent occlusion was defined as recurrence of jaundice
and/or evidence of dilated biliary systems detected by
using some imaging modality. Proximal stent migration
was defined as “located above the original stricture site”
and distal migration was defined as “located below the
original stricture site or no longer visible either endo-
scopically or radiographically”. We defined acute cholan-
gitis as elevated levels of liver and/or biliary enzymes
with the onset of fever (>38°C). We evaluated the num-
ber of endoscopic treatments until surgical resection.
Post-ERCP complications were also evaluated according
to Cotton’s criteria [13]. Additionally, we evaluated pa-
tients’ hospital stays after surgical resection and the occur-
rence of severe postoperative complications. In particular,
we evaluated the presence of severe infectious com-
plications (cholangitis that required the performance of
percutaneous or endoscopic drainage, liver abscess that
required the performance of percutaneous drainage or
resulted in sepsis).Table 2 Clinicopathological characters of the patients with in




1 BD ca (Bm) I 27
2 BD ca (Bm) I 36
3 BD ca (Bmi) I 55
4 BD ca (Bms) I 50
5 BD ca (BmjiC) I 69
6 BD ca (Bsmlrc) II 34
7 BD ca (Blcrsm) II 44
8 BD Ca (Bsmc) II DSC 124
9 BD ca (Bsmc) II DSC 114
10 BD ca (Bim) I DSC 43
11 BD ca (Bmi) I 120
12 BD ca (Bmi) I 30
13 BD ca (Bs) II DSC 141
14 BD ca (Bm) I 14
15 BD ca (Bp) IV DSC 169
16 BD ca (Bmsi) II 50
17 BD ca (Bims) II DSC 140
18 BD ca (Bsm) III DSC 117
19 BD ca (Bsclr) III DSC 116
20 GB ca (CGn) I DSC 142
21 BD ca (Brcs) III DSC 29
22 BD ca (Bs) III DSC 135
23 BD ca (Bsm) II DSC 387
24 BD ca (Bms) I DSC 107
25 BD ca (Brcsl) II DSC 110
Abbreviations: JSBS: Japanese Society of Biliary Surgery, UICC: Union for International CStatistical analysis
The statistical analysis was performed using the Stat
View program (SAS Institute, Cary, NC, USA). Categor-
ical variables were compared using the χ2 test. Continu-
ous variables were analyzed using the Student t-test. P
values of less than 0.05 were considered statistically sig-
nificant. The stent patency period was determined by
the interval between stent insertion and occlusion or by
the interval between stent insertion and surgical resec-
tion. Kaplan-Meier curves were constructed to describe
the stent patency in each group. The stent patency pe-
riods were compared using a log-rank test. To analyze
stent patency, patients without stent obstruction were
censored at the time of analysis.
Results
Fifty-seven patients were retrospectively enrolled in the
current study. Twenty-five patients were pathologically
diagnosed with Klatskin tumors, 30 with middle and
lower bile duct cancers, and 2 with gallbladder cancers.






Stage JBC Stage UICC
36 moderate Stage III Stage IIIb
48 moderate Stage III Stage IIIb
32 moderate Stage III Stage IIIb
35 poor Stage III Stage IIIb
32 moderate Stage III Stage IIIb
65 poor Stage III Stage IIIb
24 poor Stage III Stage IIIb
35 moderate Stage III Stage IIIb
35 adenosquamous Stage I Stage I
24 poor Stage III Stage IIIb
62 moderate Stage III Stage IIIb
25 moderate Stage I Stage I
25 moderate Stage I Stage I
14 well Stage II Stage II
36 moderate Stage III Stage IIIb
39 moderate Stage II Stage II
90 well Stage III Stage IIIb
40 well Stage II Stage II
55 moderate Stage II Stage II
67 moderate Stage III Stage IIIb
30 well Stage III Stage IIIb
6 well Stage I Stage I
23 well Stage I Stage I
25 moderate Stage I Stage I
45 poor Stage IVa Stage IVa
ancer Control, BD: bile duct, DSC: Down Stage Chemotherapy. RT: radiotherapy.
























70.5 (56–86) 26/6 3/6/18/3/2 4/5/7/13/3/0 20/6/5/1 39.0 (10–90) 17/11/3/1 13/19
Inside stent group 71.0 (57–84) 19/6 6/4/14/1/0 6/4/2/12/1/0 11/9/4/1 35.0 (6–90) 6/13/5/1 14/11
P value 0.378 0.732 0.817 0.453 0.510 0.612 0.320 0.155
Abbreviations: JSBS: Japanese Society of Biliary Surgery, UICC: Union for International Cancer Control.
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in Tables 1, 2 and 3. The laboratory data obtained before
endoscopic treatment was not significantly different
between the two groups (Table 4).
The clinical features at the time of the preoperative
endoscopic treatment are shown in Table 5. Eleven
patients received ENBD tube placement at the time of
initial drainage; 7 of these had acute cholangitis. In these
cases, an inside stent or a conventional stent was put in
position during the next endoscopic treatment. At the
time of the initial treatment, post-ERCP complications
occurred in 6 patients (4 cases of mild pancreatitis in
the conventional stent group and 1 case of mild pan-
creatitis and 1 case of moderate bleeding in the inside
stent group; P = 0.516). Stent migration occurred in 2 pa-
tients in the inside stent group (1 case on the proximal
side and 1 case in the distal side; P = 0.979); stent migra-
tion did not occur in any patients in the conventional
stent group. All the patients’ symptoms were alleviated fol-
lowing stent placement, and the laboratory data normal-
ized soon thereafter. The total bilirubin level normalized
at 18.0 days in the conventional stent group and at
12.9 days in the inside stent group (P = 0.438). Stent
diameters of 7, 8.5, and 10 Fr were used in 26, 3, and 3
patients in the conventional stent group and in 9, 13,
and 3 patients in the inside stent group, respectively
(P = 0.820). One, two, and three stents were used in
24, 6, and 2 patients in the conventional stent group
and in 23, 2, and 0 patients in the inside stent group,
respectively (P = 0.283).
The preoperative periods were nearly the same in the
two groups (96.3 days vs. 96.8 days). The 50% patency
periods for the stents were 49.1 days in the conventional
stent group and 85.2 days in the inside stent group










Conventional stent group 6.40 148.5 216.5
Inside stent group 5.60 123.0 139.1
P value 0.631 0.534 0.201
Abbreviations: CA19-9: Carbohydrate antigen 19–9, CEA: Carcinoembryonic antigen.cholangitis occurred during the preoperative period in 15
patients (46.9%) in the conventional stent group and in 7
patients (28%) in the inside stent group (P = 0.150). The
average number of re-interventions was 1.9 in the conven-
tional stent group and 0.32 in the inside stent group
(P = 0.026).
All patients underwent surgical resection (pancreatico-
duodenectomy, n = 33; extrahepatic bile duct resection,
n = 1; pancreaticoduodenectomy with hepatectomy, n = 1;
hepatectomy, n = 22; Table 6). The length of hospital stay
was 37.5 days in the conventional stent group and
41.7 days in the inside stent group (P = 0.560). Postopera-
tive complications occurred in 17 patients. The morbidity
rates were 34.3% (11/32) in the conventional stent group
and 24.0% (6/25) in the inside stent group. A pancreatic
fistula occurred in 4 patients (2 cases in the conventional
stent group and 2 cases in the inside stent group), and a
biliary fistula occurred in 3 patients (1 case in the conven-
tional stent group and 2 cases in the inside stent group).
Liver abscess that might be treated with percutaneous
drainage occurred in 5 patients in the conventional stent
group and in 1 patient in the inside stent group (P = 0.968).
The mortality rates were 0% (0/32) in the conventional
stent group and 4% (1/25) in the inside stent group. The
single hospital death occurred because of active bleed-
ing from a hepatic artery aneurysm in the inside stent
group.
We analyzed some of the factors associated with stent
obstruction. We describe only a few important factors
related to stent obstruction (P < 0.2) in Table 7. Inside
stent was the only significant preventative factor asso-
ciated with stent obstruction based on univariate (haz-
ard ratio [HR], 0.286; 95% confidence interval [CI],
0.114 -0.719; P = 0.008) and multivariate (HR, 0.292;














1448.8 7233.7 3.54 326.7 3.29 15/17
1279.1 8126.7 2.04 335.7 3.01 7/18
0.621 0.520 0.356 0.965 0.621 0.706






















96.3 (10–448) 18.0 (1–81) 49.1 (9–136) 15 (46.9%) 1.03 26/3/3 24/6/2
Inside stent group 96.8 (14–387) 12.9 (1–36) 85.2 (13–387) 7 (28%) 0.32 9/13/3 23/2/0
P value 0.979 0.438 0.009 0.150 0.026 0.820 0.283
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The use of inside stents in biliary stricture cases was
first reported in 1991 [10]. For benign stricture cases,
in particular, excellent outcomes were reported [8,9].
Hisatsune reported that EBS appeared to be efficacious for
the treatment of multibranched post-transplantation
biliary strictures [9]. As many as three inside stents can be
placed without requiring an endoscopic sphincterotomy
because the distal ends of these stents do not compress
the orifice of the pancreatic duct. The endoscopic place-
ment of multiple biliary stents usually requires a sphinc-
terotomy because the duodenal ends of the stents
compress the orifice of the pancreatic duct, which
sometimes leads to acute pancreatitis. In 2012, Moon
reported on the use of a modified fully covered self-
expandable metal stent [14]. The metallic stents were
put in place for the temporary treatment of benign bil-
iary strictures above the ampulla of Vater and removed
after 3 to 5 months. Technical success and improve-
ment in ductal strictures were achieved for almost all
the cases, and stent-induced bile duct injuries were not
observed.
On the other hand, evidence that an inside stent is
more useful than a conventional stent has remained in-
adequate for malignant biliary strictures. To our know-
ledge, only one prospective, randomized clinical study
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Conventional stent group (n=32)
Figure 4 Kaplan-Meier curve of patency of the stent for the
two groups. There was a statistically significant difference in the
stent patency period between the groups (P = 0.009).the intact sphincter of Oddi has been performed, by
Pedersen et al. [10]. In this previous study, the median
stent function time did not differ between the two
groups. However, significantly more patients in the in-
side stent group experienced stent migration. After the
publication of Pedersen’s findings, some retrospective
studies were also reported. Uchida assessed 16 pa-
tients with malignant biliary obstructions in whom a
stent was placed above an intact sphincter of Oddi
[15]. The median patency period was significantly lon-
ger than that for conventional stents. In their study,
most of the patients had pancreatic cancer. However,
in many patients with inoperative malignant biliary
strictures, a self-expanding metallic stent was selected
to enable a longer patency period than that for a
plastic stent [16]. Unfortunately, preoperative metallic
stent placement creates an obstacle for subsequent
surgical resection. Particularly in cases of hilar bile duct
cancer, the use of a metallic stent makes subsequent resec-
tion very difficult and risky [17]. Thus, an inside stent
seems to be a very suitable choice for preoperative stent
placement.
In this study, we selected only patients with primary
biliary tract cancer for the following reasons. First, many
patients with distal biliary strictures have pancreatic or
ampullary cancer, and the placement of an inside stent
in the biliary stricture near the distal end can be difficult
in these cases. According to past reports, the length be-
tween the lower end of the stricture and the sphincter
was more than 2 cm in all cases of hilar biliary cancer,
as well as in two-thirds of non-hilar biliary cancer cases,
while it was less than 1 cm for most pancreatic cancers
[18]. In our study, we selected only patients in whom
the distance to the lower end of the stricture was more
than 2 cm from the sphincter. Second, pancreatic cancer
in the head of the pancreas is associated with a different
type of damage to the bile epithelial cells, compared with
primary biliary tract cancer. Bile duct epithelial dysplasia
and fibrosis are secondary occurrences in patients with
pancreatic cancer. Third, cancer of the head of the pan-
creas frequently involves duodenal and perineural invasion.
Duodenal movements and/or duodenal luminal strictures
are very important factors in reflux cholangitis.
In our study, the use of an inside stent prolonged the
patency period by approximately 3 months. Recently,












Conventional stent group (4/0/0) 0 (0%) (20/1/11/0) 37.5 (13–114) 11 (34.3%) 5 (15.6%)
Inside stent Group (1/0/1) 2 (8%) (13/0/11/1) 41.7 (17–131) 6 (24.0%) 1 (4%)
P value 0.516 0.979 0.0783 0.560 0.3101 0.968
PD: pancreaticoduodenectomy, EHBD: extrahepatic bile duct resection, HR: hepatectomy HPD: pancreaticoduodenectomy with hepatectomy.
Kobayashi et al. BMC Gastroenterology  (2015) 15:8 Page 8 of 9downstage chemotherapy has been adopted by some in-
stitutions [19], and the safe performance of preoperative
chemotherapy or radiotherapy without cholangitis is
very important for these treatments. An inside stent was
more useful and suitable than a conventional stent for
the completion of these preoperative treatments. In
some previous reports, an ENBD tube was reported to
be a suitable form of drainage for hilar bile duct cancer
[20]. However, nasobiliary tube placement cannot be
endured for 2 or 3 months because of the develop-
ment of nasal ulcers, and some cases were located at the
esophagogastric junction. The long-term placement of an
ENBD tube is also not suitable for patients undergoing
preoperative chemotherapy or radiotherapy.
Many patients in the inside stent group did not require
re-intervention before surgical treatment. Stent migration
occurred in only 2 patients in the inside stent group. Ac-
cording to previous reports, stent migration occurred sig-
nificantly more frequently with an inside stent than with a
conventional stent [10]. In the present study, we did not
cut a flap at the proximal end for the inside stent, and
such a flap might have anchored the stent to the biliary
epithelium. There were some cases of obstructive jaundice
with acute cholangitis (n = 5) and without acute cholan-
gitis (n = 2) in the inside stent group. On the other hand,
all the patients experienced acute cholangitis and required
emergency endoscopic treatment in the conventional stent
group. Even if a stent obstruction occurred with an inside
stent, reflux cholangitis might occur smoothly compared
with a conventional stent. Of course, if obstructive jaun-
dice and/or acute cholangitis did happen, we might re-
move an inside stent more carefully than a conventional
stent because of the risk that the distal end of the stent
could cause injury to the biliary epithelial walls.Table 7 Univariate and multivariate analysis of stent obstruct
Univariate analysis
Hazard ratio 95% confidence interval







Stent diameter 7Fr. 1.106 0.372-3.289Post-ERCP complications did not differ significantly
between the two groups. In most cases, we did not per-
form a sphinctectomy, and the inside stent was easily
positioned in many of the cases. The papilla of Vater was
not subjected to severe damage from the use of an inside
stent, compared with the use of a conventional stent. The
conventional stent was associated with a higher tendency
of pancreatic duct obstruction, compared with the inside
stent. In our study, bleeding occurred in 1 patient in the
inside stent group. This patient experienced an injury at
the esophagogastric junction at the time of the removal of
the inside stent. This complication did not seem to be a
specific accident arising from the use of an inside stent.
Preoperative cholangitis is reportedly a risk factor for
hepatic insufficiency following major hepatic resection
[21]. Sakata et al. evaluated the effects of preoperative
cholangitis on in-hospital mortality among patients with
hilar cholangiocarcinoma. They found that the mortality
rate was higher among patients with cholangitis than
among those without this complication, and cholangitis
was the only independent variable related to postopera-
tive in-hospital mortality. In the current study, only 1
case of severe infection occurred after surgical resection
in the inside stent group. With regard to this point, the
use of an inside stent might be suitable for the preven-
tion of postoperative complications.
We also analyzed some of the important factors re-
lated to stent obstruction. EST, Bismuth classification,
and stent diameter were not significant preventative fac-
tors associated with stent obstruction in this study (data
not shown). We should re-analyze these factors in a
large number of patients, but it is very important that
according to our findings, inside stent was the only sig-
nificant preventative factor.ion
Multivariate analysis
P value Hazard ratio 95% confidence interval P value
0.008 0.292 0.114-0.750 0.011
0.118 1.614 0.579-4.499 0.360
0.151 2.530 0.807-7.934 0.111
0.8558
Kobayashi et al. BMC Gastroenterology  (2015) 15:8 Page 9 of 9This study was not a randomized study, and the skill
of the individual endoscopist might have differed
slightly between the two groups. However, all the treat-
ments were performed by the same three expert en-
doscopists (with 20, 16, and 15 years of experience,
respectively). Thus, any technical bias is likely to be very
small in this study. However, there is some selection
bias in this study. Patient selection bias (obstructive
jaundice with cholangitis in initial treatment, chemo-
therapy before surgical resection, stent diameter, stent
length, among others) could not rule out in this retro-
spective study.
Conclusion
In summary, the endoscopic treatment of biliary strictures
using an inside stent is very useful and safe. Furthermore,
the stent patency of inside stent was significantly longer
than that of conventional stents. In addition, the incidence
of acute cholangitis and the need for reintervention or
emergency intervention were notably lower in the inside
stent group. Post-ERCP and postoperative complications
did not differ significantly between the two groups. We
propose that the use of an inside stent as a temporary pre-
operative stent might be useful in patients with primary
biliary tract cancer.
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